NEW! Rapid Learn + Listen package
CAR T-cell therapy
CAR T-cell therapy is a treatment that re-engineers a patient’s T-cells with synthetic proteins called chimeric antigen receptors (CARs) which enhance the T-cell’s ability to recognise and kill cancer cells. It has proven effective in some diseases including B-cell malignancies, although it is not effective in all patient populations.
Our rapid learning package includes a 5-minute mini-module to help you:
- explain how CAR T-cell therapy works to treat some cancers
- identify the indications for CAR T-cell therapy
- describe the CAR T-cell therapy clinical process
- list common toxicities associated with CAR T-cell therapy and identify their signs and symptoms.
Learn more in the CAR T rapid learning →
"I hope that as time progresses CAR T becomes a viable option for many more patients and is brought forward in the treatment line."
Erica Smeaton, National Nurse Manager at Lymphoma Australia and Lymphoma CNC.
Listen to Erica Smeaton discuss two CAR T clinical case studies and their outcomes.
Listen to the case study podcast →
Watch now! Emerging treatment and care in hepatocellular carcinoma webinar
The first Cancer Conversations webinar for 2022 was held last week, focussing on the most common type of primary liver cancer in adults, hepatocellular carcinoma (HCC).
The one-hour webinar delved into the prevention, early diagnosis, treatment and care of HCC and featured expert panel discussion and presentations from a multidisciplinary perspective.
Watch the webinar now! →
View the 2022 Cancer Conversations schedule →
We've made some great progress with ADAC, thanks to our incredibly dedicated reviewers! Module 2 is undergoing user testing with our External Review Group, and Module 7 is on track to begin building next week!
We're looking forward to training our wonderful ADAC facilitators in Brisbane so they are ready to implement the new version in their facilities!
We are still inviting participation via live streaming and face to face, however travel requests have now closed.
New version: Oral anti-cancer drugs in community pharmacy
Share with your community pharmacy colleagues now!
We've done a comprehensive update to our Oral anti-cancer drugs in community pharmacy course to ensure community pharmacists understand the supply, safe handling, adverse effects, supportive care and potential issues surrounding oral anti-cancer treatments.
The new 6-part accredited eLearning has been developed by national cancer pharmacists, community pharmacists and peak professional bodies and supports the expanding role of community pharmacists in managing patients receiving oral anti-cancer drugs.
View the new course now →
eviQ protocol updates
Subscribe to receive content area specific updates direct to your inbox - click here to sign up to eviQ newsletters.
eviQ also lists all recently added protocols and updates made in the past 90 days on their content area homepages: Cancer genetics Haematology and BMT Medical oncology Radiation oncology, Clinical resources
eviQ Education flyers available for your practice - Featuring a catalogue of all our courses. You can now print your own flyer to display in your workplace.
Rapid Learning series - New to Rapid learning? Browse our Rapid Learning library.
Rapid Listening series - Listen to clinical case studies on our website, or listen/subscribe to the podcasts on Spotify or Google Podcasts.
Facilitator training: Register for on-demand facilitator training and/or an online Q & A session webinar:
- ADAC Q & A session - Wednesday 11th May 2022 at 2.00 - 3.00 pm (AEDT)
View the training calendar here.
Want to know what's new? Keep an eye on our website newsfeed.
Share the love: If you have a colleague who may be interested in receiving this update – please invite them to subscribe! If you have a link you'd like to share, think about tweeting it with hashtag #eviQ .
Q: "I'm an ADAC Facilitator. Can I still register for the ADAC V4 train the trainer forum in June?"
A: Registrations are still open for live-stream/videoconferencing attendees, and those who would like to be there in person - however applications for travel requests have closed.
Register for ADAC V4 training →
Did you know?
The toxicities associated with CAR T-cell therapy can include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), B-cell aplasia and cytopenias.
Learn more with our CAR T cell Rapid Learn + Listen →